Watson’s nabumetone tablets get FDA OK
PARSIPPANY, N.J. — The Food and Drug Administration has approved a drug for arthritis made by Watson Pharmaceuticals, Watson said Friday.
The drug maker announced the approval of nabumetone tablets in the 500-mg and 750-mg strength. The drug is used to treat signs and symptoms of rheumatoid arthritis and osteoarthritis.
Nabumetone had sales of $58 million during the 12-month period ended in April, according to IMS Health.
FDA updates ongoing safety review of Actos
SILVER SPRING, Md. — The Food and Drug Administration on Thursday informed the public that continued use of a Type 2 diabetes treatment made by Takeda Pharmaceuticals for more than one year may be associated with an increased risk of bladder cancer.
As part of its ongoing safety review of Actos (pioglitazone), the FDA said that information about this risk will be added to the "warnings and precautions" section of the label for the drug and other pioglitazone-containing medicines. In response, Takeda said that it "is working with [the] FDA to make appropriate updates to the prescribing information."
The drug maker also confirmed that it is supporting a 10-year epidemiological study that investigates the questions raised about the association of Actos and bladder cancer. The study, which commenced in 2002, is being conducted by the University of Pennsylvania and Kaiser Permanente Diabetes Registry of Northern California. Takeda noted it will support the study through its conclusion at the end of 2012 and will report on the study results upon completion.
Report: EMR market to pass $6 billion mark by 2015
DALLAS — The market for electronic medical records in the United States may exceed $6 billion in value in five years, according to a new report by research firm MarketsandMarkets.
In the report, “U.S. Electronic Medical Records (EMR) Market, 2010-2015 (Market Share, Winning Strategies and Adoption Trends),” released this month, the firm said that the market was expected to grow from $2.17 billion in 2009 to $6.05 billion in 2015.
The report noted that the electronic medical record market space in the United States is “highly fragmented,” with Allscripts’ 15.7% share dominating a physician office EMR market that includes more than 1,000 players.